News
News
Local News
Crime & Public Safety
Your Tax Dollars At Work
Politics
Massachusetts
Nation
World
Business
Health
Weather
Columnists
Traffic
Sports
Sports
Red Sox
Patriots
Celtics
Bruins
College
High School
More Sports
Scores & Stats
Entertainment
Entertainment
Celebrity News
Arts & Culture
Movies
Television
Music
Fun & Games
Horoscope
Lottery
Comics
Puzzles
Lifestyle
Lifestyle
Food & Beverage
Travel
Style & Fashion
Obituaries
Obituaries
Local Obituaries
Submit an Obituary
Opinion
Opinion
Editorials
Op-Ed
Letters
Submit a Letter
Radio
Weather
E-Edition
Subscribe
Sign Up For Newsletters
News
News
Local News
Crime & Public Safety
Your Tax Dollars At Work
Politics
Massachusetts
Nation
World
Business
Health
Weather
Columnists
Traffic
Sports
Sports
Red Sox
Patriots
Celtics
Bruins
College
High School
More Sports
Scores & Stats
Entertainment
Entertainment
Celebrity News
Arts & Culture
Movies
Television
Music
Fun & Games
Horoscope
Lottery
Comics
Puzzles
Lifestyle
Lifestyle
Food & Beverage
Travel
Style & Fashion
Obituaries
Obituaries
Local Obituaries
Submit an Obituary
Opinion
Opinion
Editorials
Op-Ed
Letters
Submit a Letter
Radio
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Small Pharma Inc.
Small Pharma Reports Fiscal Second Quarter 2024 Highlights
October 19, 2023
From
Small Pharma Inc.
Via
GlobeNewswire
Tickers
DMTTF
TSX-V:DMT
Small Pharma Announces Voting Results from Annual General and Special Meeting of Shareholders
October 12, 2023
From
Small Pharma Inc.
Via
GlobeNewswire
Tickers
DMTTF
TSX-V:DMT
Small Pharma Reports Positive Top-line Data from SPL026 (DMT)-SSRI Drug Interaction Study in Patients with Major Depressive Disorder
September 26, 2023
From
Small Pharma Inc.
Via
GlobeNewswire
Tickers
DMTTF
TSX-V:DMT
Small Pharma Reports Fiscal First Quarter 2024 Highlights
July 27, 2023
From
Small Pharma Inc.
Via
GlobeNewswire
Tickers
DMTTF
TSX-V:DMT
Small Pharma Announces SPL028 R&D Strategy Update
July 05, 2023
From
Small Pharma Inc.
Via
GlobeNewswire
Tickers
DMTTF
TSX-V:DMT
Small Pharma Announces Management Team Change
July 05, 2023
From
Small Pharma Inc.
Via
GlobeNewswire
Tickers
DMTTF
TSX-V:DMT
Small Pharma Reports Financial Results for the Fiscal Year Ended February 28, 2023 and Recent Business Highlights
June 28, 2023
From
Small Pharma Inc.
Via
GlobeNewswire
Tickers
DMTTF
TSX-V:DMT
Small Pharma Announces Significant Developments In Intellectual Property Portfolio
May 25, 2023
From
Small Pharma Inc.
Via
GlobeNewswire
Tickers
DMTTF
TSX-V:DMT
Small Pharma to Present at Upcoming CINP World Congress of Neuropsychopharmacology
May 03, 2023
From
Small Pharma Inc.
Via
GlobeNewswire
Tickers
DMTTF
TSX-V:DMT
Small Pharma Announces Positive Six-month Data from Phase IIa Trial of SPL026
April 04, 2023
From
Small Pharma Inc.
Via
GlobeNewswire
Tickers
DMTTF
TSX-V:DMT
Small Pharma to Host Virtual Roundtable Event with Key Opinion Leaders in Psychiatry
March 07, 2023
From
Small Pharma Inc.
Via
GlobeNewswire
Tickers
DMTTF
TSX-V:DMT
Small Pharma Announces Further Positive Data from SPL026 Phase IIa Trial in Major Depressive Disorder Strengthening Topline Efficacy Results
March 07, 2023
From
Small Pharma Inc.
Via
GlobeNewswire
Tickers
DMTTF
TSX-V:DMT
Small Pharma to Present at Cowen’s 43rd Annual Health Care Conference
March 01, 2023
From
Small Pharma Inc.
Via
GlobeNewswire
Tickers
DMTTF
TSX-V:DMT
First Subject Dosed in Small Pharma’s First-in-Human Phase I Clinical Trial with SPL028
February 15, 2023
From
Small Pharma Inc.
Via
GlobeNewswire
Tickers
DMTTF
TSX-V:DMT
Small Pharma Announces Update on Intellectual Property Portfolio with Two New Patents Approved for Issue
February 01, 2023
From
Small Pharma Inc.
Via
GlobeNewswire
Tickers
DMTTF
TSX-V:DMT
Small Pharma Reports Fiscal Third Quarter 2023 Highlights
January 25, 2023
From
Small Pharma Inc.
Via
GlobeNewswire
Tickers
DMTTF
TSX-V:DMT
Small Pharma Reports Positive Top-line Results from Phase IIa Trial of SPL026 in Major Depressive Disorder
January 25, 2023
From
Small Pharma Inc.
Via
GlobeNewswire
Tickers
DMTTF
TSX-V:DMT
Small Pharma To Announce Results of SPL026 Phase IIa Trial for Major Depressive Disorder and Host Conference Call on Wednesday, January 25
January 24, 2023
From
Small Pharma Inc.
Via
GlobeNewswire
Tickers
DMTTF
TSX-V:DMT
First Patient Dosed in Small Pharma’s Phase I Study Exploring Intramuscular Administration of SPL026
January 09, 2023
From
Small Pharma Inc.
Via
GlobeNewswire
Tickers
DMTTF
TSX-V:DMT
Small Pharma Announces Completion of SPL026 Phase IIa Trial and Secures New Intellectual Property
December 22, 2022
From
Small Pharma Inc.
Via
GlobeNewswire
Tickers
DMTTF
TSX-V:DMT
First Patient Dosed in Small Pharma’s Drug Interaction Study
December 15, 2022
From
Small Pharma Inc.
Via
GlobeNewswire
Tickers
DMTTF
TSX-V:DMT
Small Pharma To Support University College London Research Project on Neuroplasticity
December 14, 2022
From
Small Pharma Inc.
Via
GlobeNewswire
Tickers
DMTTF
TSX-V:DMT
Small Pharma to Participate in Upcoming Canaccord Genuity Investor Symposium
December 08, 2022
From
Small Pharma Inc.
Via
GlobeNewswire
Tickers
DMTTF
TSX-V:DMT
Small Pharma to Participate in November Investor and Healthcare Conferences
November 11, 2022
From
Small Pharma Inc.
Via
GlobeNewswire
Tickers
DMTTF
TSX-V:DMT
Small Pharma Receives Approval for First-In-Human Phase I Clinical Trial With SPL028
October 31, 2022
From
Small Pharma Inc.
Via
GlobeNewswire
Tickers
DMTTF
TSX-V:DMT
Second United States Patent Granted for Small Pharma’s Psychedelics Portfolio
October 19, 2022
From
Small Pharma Inc.
Via
GlobeNewswire
Tickers
DMTTF
TSX-V:DMT
Small Pharma Reports Fiscal Second Quarter 2023 Highlights
October 14, 2022
From
Small Pharma Inc.
Via
GlobeNewswire
Tickers
DMTTF
TSX-V:DMT
U.S. Patent Grant to Strengthen Small Pharma’s DMT Patent Strategy With Injectable Formulation
July 26, 2022
From
Small Pharma Inc.
Via
GlobeNewswire
Tickers
DMTTF
TSX-V:DMT
Small Pharma Inc.: World’s First Clinical Trial For DMT-Assisted Therapy in Major Depressive Disorder Shows Consistent Quality of Psychedelic Response in Phase I
February 22, 2022
From
Small Pharma Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Close